Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $319
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on BeiGene (NASDAQ:BGNE) but lowers the price target from $321 to $319.
August 29, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley maintains an Overweight rating on BeiGene but lowers the price target from $321 to $319.
The news is directly about BeiGene and is likely to impact its stock price. While the Overweight rating is maintained, indicating a positive outlook, the lowering of the price target might create some uncertainty among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100